Esperion Therapeutics Insider Sells Over 11,800 Shares

Benjamin Looker, Chief Legal Officer, sold shares worth $37,363.84.

Written by EarningsIQ · Published Jun 19, 2026, 3:01 AM EDT · Updated Jun 20, 2026, 9:00 AM EDT

Key Points

Benjamin Looker, the Chief Legal Officer at Esperion Therapeutics, sold 11,824 shares at an average price of $3.16 each, totaling $37,363.84 on June 17, 2026.
Esperion Therapeutics, listed on NasdaqGM under the ticker ESPR, has a market cap of about $811.7 million with a forward P/E of 10.79 and a beta of 1.067.
HC Wainwright & Co. downgraded Esperion to a hold rating with a $3.16 price target on May 1, 2026, while Citizens maintained a buy rating with a $5 target on March 13, 2026.

Benjamin Looker, the Chief Legal Officer at Esperion Therapeutics, Inc. (NasdaqGM: ESPR), recently sold 11,824 shares of the company. The transaction, which took place on June 17, 2026, was valued at $37,363.84, with each share priced at $3.16. This sale was not part of a pre-planned trading program.

Insider Buying and Selling at Esperion Therapeutics, Inc.

In addition to Looker's transaction, several other insiders at Esperion were active in the market. On the same day, CFO Benjamin Halladay sold 10,773 shares at the same price. President and CEO Sheldon Koenig also parted with 53,588 shares. Earlier, on May 28, 2026, insiders including Seth Fischer, John Craig Thompson, and Robert Hoffman each bought 79,873 shares.

Other Institutional Activity in Esperion Therapeutics

Several institutional investors made changes to their holdings in Esperion. BlackRock, Inc. added 170,226 shares, bringing its total to 17,852,427 shares valued at approximately $48.9 million. Wasatch Advisors LP significantly increased its position by 6,323,138 shares, totaling 15,768,897 shares worth about $43.2 million. Meanwhile, Two Seas Capital LP reduced its stake by 507,688 shares, now holding 11,394,833 shares valued at $31.2 million.

Esperion Therapeutics Stock Snapshot

Shares of Esperion Therapeutics are trading around $3.17. The company has a market capitalization of approximately $811.7 million and a forward P/E ratio of 10.79, indicating potential profitability. The stock's beta is 1.067, suggesting slightly higher volatility compared to the market. Over the past year, the stock has ranged between $0.95 and $4.18, with a 50-day moving average of $2.78 and a 200-day moving average of $3.02.

Analysts Set New Price Targets

On May 1, 2026, HC Wainwright & Co. downgraded Esperion Therapeutics to a hold rating, setting a price target of $3.16. Earlier in March, Citizens maintained a buy rating with a target of $5. Needham also maintained its buy rating with the same $5 target in March. Overall, the consensus among analysts is a neutral outlook with a mean price target of $3.19 based on four opinions.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a biopharmaceutical company based in Ann Arbor, Michigan. It focuses on developing and commercializing oral, non-statin medications for lowering LDL cholesterol in patients. Its key products include NEXLETOL and NEXLIZET, which are used to treat primary hyperlipidemia in adults. The company collaborates with partners like Daiichi Sankyo and Otsuka Pharmaceutical to expand its reach. Esperion is led by CEO Sheldon L. Koenig and employs around 294 people.

Bottom Line

Benjamin Looker's recent sale of shares in Esperion Therapeutics is part of ongoing insider activity at the company. Investors often watch insider transactions for potential signals, though they are not definitive indicators of future performance. As always, these trades are disclosed after the fact, providing a snapshot of insider sentiment at a specific time.